Information de reference pour ce titreAccession Number: | 01337336-201207000-00014.
|
Author: | Deftereos, Spyros N *,2; Dodou, Evie 1; Andronis, Christos 1; Persidis, Aris 1
|
Institution: | (1,2)Biovista Inc, 2421 Ivy Road, Charlottesville, VA 22903, USA
|
Title: | From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.[Review]
|
Source: | Expert Review of Clinical Pharmacology. 5(4):413-425, July 2012.
|
Abstract: | : Initially introduced in the 1950s for treating depression, monoamine oxidase (MAO) inhibitors were gradually abandoned, mainly owing to their potential for drug-drug and drug-food interactions, the most widely known being with tyramine-containing food (the 'cheese' effect). Since then, more selective MAO-A or MAO-B inhibitors have been developed with substantially reduced risks, and have been approved for the treatment of depression and Parkinson's disease, respectively. Recent research suggests that some of these drugs also have neuroprotective properties, while preclinical evidence expands the spectrum of potential indications to heart failure, renal diseases and multiple sclerosis. In this article, the authors review the relevance of MAO isoforms to disease, and they also outline current research and development efforts in this class of drugs, including newer multipotent compounds.
(C) 2012 Expert Reviews, Ltd.
|
Author Keywords: | Alzheimer's disease; cardiac failure; depression; monoamine oxidase; monoamine oxidase-A; monoamine oxidase-B; multiple sclerosis; Parkinson's disease; renal disease.
|
References: | 1 Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve. Clin. J. Med. 77(12), 859-882 (2010).
2 Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 25(1-2), 215-221 (2004).* Good review of the pharmacology and safety of monoamine oxidase (MAO) inhibitors.
3 Pletscher A. The discovery of antidepressants: a winding path. Experientia 47(1), 4-8 (1991).
4 Slattery DA, Hudson AL, Nutt DJ. Invited review: the evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 18(1), 1-21 (2004).
5 Bonnet U. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug Rev. 8(3), 283-308 (2002).
6 Branco JC, Tome AM, Cruz MR, Filipe A. Pirlindole in the treatment of depression and fibromyalgia syndrome. Clin. Drug Investig. 31(10), 675-689 (2011).
7 Macedo A, Leiria E, Filipe A. Pirlindole in the treatment of depression: a meta-analysis. Clin. Drug Investig. 31(1), 61-71 (2011).
8 Bun'kova KM. [Efficacy and tolerability of clomipramine, pirlindole and escitalopram in the treatment of neurotic level depression]. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 108(3), 29-32 (2008).
9 Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 9(1), 97-140 (2003).
10 Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25(12), 1061-1071 (2011).
11 Riederer P, Laux G. MAO-inhibitors in Parkinson's Disease. Exp. Neurobiol. 20(1), 1-17 (2011).* Good review of the role of MAO inhibitors in Parkinson's disease.
12 Olanow CW, Hauser RA, Jankovic J et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease-modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 23(15), 2194-2201 (2008).
13 Olanow CW, Rascol O, Hauser R et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361(13), 1268-1278 (2009).** A Phase III trial examining the potential neuroprotective effects of rasagiline in Parkinson's disease. It indicated discordant effects of two different doses of rasagiline and gave rise to scientific debate.
14 Birkmayer W, Knoll J, Riederer P, Youdim MB. (-)-Deprenyl leads to prolongation of l-Dopa efficacy in Parkinson's disease. Mod. Probl. Pharmacopsychiatry 19, 170-176 (1983).
15 Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 64(2), 113-127 (1985).
16 Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip. Rev. Syst. Biol. Med. 3(3), 323-334 (2011).
17 Lekka E, Deftereos SN, Persidis A, Persidis A, Andronis C. Literature analysis for systematic drug repurposing: a case study from Biovista. Drug Discov. Today 8(3-4), 103-108 (2011).
18 Deftereos SN, Andronis C, Virvillis V, Konstanti O, Persidis A. Dimebon ameliorates disease severity in the mog-induced experimental allergic encephalomyelitis (Eae) animal model of progressive multiple sclerosis (MS). Presented at: 135th Annual Meeting of the American Neurological Association. San Francisco, CA, USA, 12-15 September 2010.* Preclinical evidence on the role of Pirlindol in multiple sclerosis.
19 Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim. Biophys. Acta 1813(7), 1323-1332 (2011).* Review of the role of MAO-A in cardiac failure.
20 Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J. Psychiatry Neurosci. 18(5), 214-225 (1993).
21 Billett EE. Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology 25(1-2), 139-148 (2004).
22 Grimsby J, Lan NC, Neve R, Chen K, Shih JC. Tissue distribution of human monoamine oxidase A and B mRNA. J. Neurochem. 55(4), 1166-1169 (1990).
23 Bach AW, Lan NC, Johnson DL et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. Natl Acad. Sci. USA 85(13), 4934-4938 (1988).
24 Fowler JS, Alia-Klein N, Kriplani A et al. Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol. Psychiatry 62(4), 355-358 (2007).
25 Kalaria RN, Mitchell MJ, Harik SI. Monoamine oxidases of the human brain and liver. Brain 111 (Pt 6), 1441-1451 (1988).
26 Shih JC, Grimsby J, Chen K. The expression of human MAO-A and B genes. J. Neural Transm. Suppl. 32, 41-47 (1990).
27 Saura J, Nadal E, van den Berg B, Vila M, Bombi JA, Mahy N. Localization of monoamine oxidases in human peripheral tissues. Life Sci. 59(16), 1341-1349 (1996).
28 Pena-Silva RA, Miller JD, Chu Y, Heistad DD. Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am. J. Physiol. Heart Circ. Physiol. 297(4), H1354-H1360 (2009).
29 Fowler JS, MacGregor RR, Wolf AP et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 235(4787), 481-485 (1987).
30 Jahng JW, Houpt TA, Wessel TC, Chen K, Shih JC, Joh TH. Localization of monoamine oxidase A and B mRNA in the rat brain by in situ hybridization. Synapse 25(1), 30-36 (1997).
31 Kalgutkar AS, Dalvie DK, Castagnoli N Jr, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol. 14(9), 1139-1162 (2001).
32 Binda C, Wang J, Pisani L et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem. 50(23), 5848-5852 (2007).
33 Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl Acad. Sci. USA 100(17), 9750-9755 (2003).
34 Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 9(1), 22-26 (2002).
35 De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl Acad. Sci. USA 102(36), 12684-12689 (2005).
36 Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 11(15), 1983-1993 (2004).
37 Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 118(7), 979-986 (2011).
38 Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262(5133), 578-580 (1993).
39 Ishii M, Shimizu S, Sakairi Y et al. MAOA, MTHFR, and TNF-[beta] genes polymorphisms and personality traits in the pathogenesis of migraine. Mol. Cell. Biochem. 363(1-2), 357-366 (2012).
40 Sun Y, Zhang J, Yuan Y, Yu X, Shen Y, Xu Q. Study of a possible role of the monoamine oxidase A (MAOA) gene in paranoid schizophrenia among a Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B(1), 104-111 (2012).
41 Li JJ, Lee SS. Association of positive and negative parenting behavior with childhood adhd: interactions with offspring monoamine oxidase A (MAO-A) genotype. J. Abnorm. Child Psychol. 40(2), 165-175 (2012).
42 Liu L, Guan LL, Chen Y et al. Association analyses of MAOA in Chinese Han subjects with attention-deficit/hyperactivity disorder: family-based association test, case-control study, and quantitative traits of impulsivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B(6), 737-748 (2011).
43 Tassone F, Qi L, Zhang W, Hansen RL, Pessah IN, Hertz-Picciotto I. MAOA, DBH, and SLC6A4 variants in CHARGE: a case-control study of autism spectrum disorders. Autism Res. 4(4), 250-261 (2011).
44 Beaver KM, DeLisi M, Vaughn MG, Barnes JC. Monoamine oxidase A genotype is associated with gang membership and weapon use. Compr. Psychiatry 51(2), 130-134 (2010).
45 Huang SY, Lin MT, Lin WW, Huang CC, Shy MJ, Lu RB. Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population. World J. Biol. Psychiatry 10(4 Pt 2), 544-551 (2009).
46 Lung FW, Tzeng DS, Huang MF, Lee MB. Association of the MAOA promoter uVNTR polymorphism with suicide attempts in patients with major depressive disorder. BMC Med. Genet. 12, 74 (2011).
47 Du L, Faludi G, Palkovits M, Sotonyi P, Bakish D, Hrdina PD. High activity-related allele of MAO-A gene associated with depressed suicide in males. Neuroreport 13(9), 1195-1198 (2002).
48 Zhang J, Chen Y, Zhang K et al. A cis-phase interaction study of genetic variants within the MAOA gene in major depressive disorder. Biol. Psychiatry 68(9), 795-800 (2010).
49 Scott AL, Bortolato M, Chen K, Shih JC. Novel monoamine oxidase A knock out mice with human-like spontaneous mutation. Neuroreport 19(7), 739-743 (2008).
50 Bortolato M, Chen K, Godar SC et al. Social deficits and perseverative behaviors, but not overt aggression, in MAO-A hypomorphic mice. Neuropsychopharmacology 36(13), 2674-2688 (2011).
51 Kiyohara C, Miyake Y, Koyanagi M et al.; Fukuoka Kinki Parkinson's Disease Study Group. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population. BMC Neurol. 11, 89 (2011).
52 Wei YL, Li CX, Li SB, Liu Y, Hu L. Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese. Behav. Brain Funct. 7, 42 (2011).
53 Dlugos AM, Palmer AA, de Wit H. Negative emotionality: monoamine oxidase B gene variants modulate personality traits in healthy humans. J. Neural Transm. 116(10), 1323-1334 (2009).
54 Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. Mol. Cell. Biochem. 312(1-2), 131-138 (2008).
55 Li J, Wang Y, Hu S et al. The monoamine oxidase B gene exhibits significant association to ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147(3), 370-374 (2008).
56 Devor EJ, Cloninger CR, Hoffman PL, Tabakoff B. Association of monoamine oxidase (MAO) activity with alcoholism and alcoholic subtypes. Am. J. Med. Genet. 48(4), 209-213 (1993).
57 Faraj BA, Davis DC, Camp VM, Mooney AJ 3rd, Holloway T, Barika G. Platelet monoamine oxidase activity in alcoholics, alcoholics with drug dependence, and cocaine addicts. Alcohol. Clin. Exp. Res. 18(5), 1114-1120 (1994).
58 Grimsby J, Toth M, Chen K et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet. 17(2), 206-210 (1997).
59 Bortolato M, Godar SC, Davarian S, Chen K, Shih JC. Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 34(13), 2746-2757 (2009).
60 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 13(10), 855-870 (2008).** Good review of the role of MAO inhibitors in depression.
61 Henkel V, Mergl R, Allgaier AK, Kohnen R, Moller HJ, Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res. 141(1), 89-101 (2006).
62 Rothschild R, Quitkin HM, Quitkin FM et al. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. Int. J. Eat. Disord. 15(1), 1-9 (1994).
63 Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can. J. Psychiatry 51(12), 783-790 (2006).
64 Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J. Clin. Psychiatry 64(2), 208-214 (2003).
65 Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J. Clin. Psychopharmacol. 26(6), 579-586 (2006).
66 Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311(7020), 1602-1607 (1995).
67 Myllyla VV, Sotaniemi KA, Hakulinen P, Maki-Ikola O, Heinonen EH. Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurol. Scand. 95(4), 211-218 (1997).
68 Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59(12), 1937-1943 (2002).
69 Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62(2), 241-248 (2005).
70 Rascol O, Brooks DJ, Melamed E et al.; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463), 947-954 (2005).
71 Deftereos SN, Andronis CA. Discordant effects of rasagiline doses in Parkinson disease. Nat. Rev. Neurol. 6(7), 1p following 410 (2010).
72 Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int. J. Geriatr. Psychiatry 17(2), 175-183 (2002).
73 Carrillo MC, Minami C, Kitani K et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 67(5), 577-585 (2000).
74 Mialet-Perez J, Bianchi P, Kunduzova O, Parini A. New insights on receptor-dependent and monoamine oxidase-dependent effects of serotonin in the heart. J. Neural Transm. 114(6), 823-827 (2007).
75 Bianchi P, Pimentel DR, Murphy MP, Colucci WS, Parini A. A new hypertrophic mechanism of serotonin in cardiac myocytes: receptor-independent ROS generation. FASEB J. 19(6), 641-643 (2005).
76 Maurel A, Hernandez C, Kunduzova O et al. Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am. J. Physiol. Heart Circ. Physiol. 284(4), H1460-H1467 (2003).
77 Kaludercic N, Takimoto E, Nagayama T et al. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ. Res. 106(1), 193-202 (2010).
78 Bianchi P, Kunduzova O, Masini E et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112(21), 3297-3305 (2005).
79 Beau SL, Saffitz JE. Transmural heterogeneity of norepinephrine uptake in failing human hearts. J. Am. Coll. Cardiol. 23(3), 579-585 (1994).
80 Backs J, Haunstetter A, Gerber SH et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J. Mol. Cell. Cardiol. 33(3), 461-472 (2001).
81 Dorris RL. A simple method for screening monoamine oxidase (MAO) inhibitory drugs for type preference. J. Pharmacol. Methods 7(2), 133-137 (1982).
82 Wang Y, Berndt TJ, Gross JM, Peterson MA, So MJ, Knox FG. Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(1), R248-R254 (2001).
83 Soares-da-Silva P, Vieira-Coelho MA, Pinto-do-O PC, Pestana M, Bertorello AM. Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens. Res. 18(Suppl. 1), S47-S51 (1995).
84 Itskovitz HD, Chen YH, Stier CT Jr. Reciprocal renal effects of dopamine and 5-hydroxytryptamine formed within the rat kidney. Clin. Sci. 75(5), 503-507 (1988).
85 Weinman EJ, Biswas R, Steplock D et al. Increased renal dopamine and acute renal adaptation to a high-phosphate diet. Am. J. Physiol. Renal Physiol. 300(5), F1123-F1129 (2011).
86 Pizzinat N, Remaury A, Parini A. The renal monoamine oxidases: pathophysiology and targets for therapeutic intervention. Curr. Opin. Nephrol. Hypertens. 7(1), 33-36 (1998).* Review of the role of MAO in the kidney.
87 Chaaya R, Alfarano C, Guilbeau-Frugier C et al. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol. Dial. Transplant. 26(2), 489-498 (2011).
88 Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J. Neuropsychiatry Clin. Neurosci. 11(2), 271-273 (1999).
89 Then Bergh F, Kumpfel T, Grasser A, Rupprecht R, Holsboer F, Trenkwalder C. Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial. J. Clin. Endocrinol. Metab. 86(4), 1610-1615 (2001).
90 Musgrave T, Tenorio G, Rauw G, Baker GB, Kerr BJ. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Neurochem. Int. 59(1), 28-38 (2011).
91 Musgrave T, Benson C, Wong G et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav. Immun. 25(8), 1677-1688 (2011).
92 Remick RA, Froese C. Monoamine oxidase inhibitors: clinical review. Can. Fam. Physician 36, 1151-1155 (1990).
93 Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 155(1), 154-164 (1965).
94 Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 132(2), 500-506 (2001).
95 Zelapar(R), package insert. VALEANT Pharmaceuticals, NJ, USA.
96 Eldepryl(TM), package insert. Somerset Pharmaceuticals, FL, USA.
97 Emsam(R), package insert. Somerset Pharmaceuticals, FL, USA.
98 Finberg JP, Tenne M, Youdim MB. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. 73(1), 65-74 (1981).
99 Azilect(R), package insert. TEVA Neuroscience, MO, USA.
100 Kahn R, Gorgon L, Jones K et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob. Res. 14(3), 377-382 (2012).
101 LeWitt PA, Taylor DC. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 5(2), 210-225 (2008).
102 Parkinson Study Group. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Arch. Neurol. 51(4), 342-347 (1994).
103 The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol. 40, 99-107 (1996).
104 Bergstrom M, Westerberg G, Nemeth G et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur. J. Clin. Pharmacol. 52(2), 121-128 (1997).
105 Raaflaub J, Haefelfinger P, Trautmann KH. Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforschung. 34(1), 80-82 (1984).
106 Andreeva N, Asnina V, Liberman S. Domestic antidepressants. 2. Pyrazidole (pirlindole). Pharm. Chem. J. 34, 465-470 (2000).
107 Bruhwyler J, Liegeois JF, Geczy J. Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol. Res. 36(1), 23-33 (1997).
108 Emilien G. Befloxatone (Synthelabo). IDrugs 2(3), 247-253 (1999).
109 Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17(7), 1285-1297 (1968).
110 Lader MH, Sakalis G, Tansella M. Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 18(1), 118-123 (1970).
111 Sandler M, Glover V, Ashford A, Stern GM. Absence of "cheese effect" during deprenyl therapy: some recent studies. J. Neural Transm. 43(3-4), 209-215 (1978).
112 Anderson MC, Hasan F, McCrodden JM, Tipton KF. Monoamine oxidase inhibitors and the cheese effect. Neurochem. Res. 18(11), 1145-1149 (1993).
113 Stocchi F, Borgohain R, Onofrj M et al.; Study 015 Investigators. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov. Disord. 27(1), 106-112 (2012).
114 Pevarello P, Bonsignori A, Dostert P et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J. Med. Chem. 41(4), 579-590 (1998).
115 Caccia C, Maj R, Calabresi M et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 67(7 Suppl. 2), S18-S23 (2006).
116 Weinreb O, Amit T, Bar-Am O, Youdim MB. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int. Rev. Neurobiol. 100, 191-215 (2011).
117 Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann. NY Acad. Sci. 939, 148-161 (2001).
118 Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MB. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits. Neuropharmacology 43(6), 999-1005 (2002).
119 Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. NY Acad. Sci. 1122, 155-168 (2007).
120 Kita K, Hirayama K. Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology 38(7), 1095-1099 (1988).
121 Traut M, Brode E, Hoffmann HD. Pharmacology of amezinium, a novel antihypotensive drug. IV. Biochemical investigations of the mechanism of action. Arzneimittelforschung. 31(9a), 1566-1574 (1981).
122 Jacob G, Gamboa A, Diedrich A, Shibao C, Robertson D, Biaggioni I. Tyramine-induced vasodilation mediated by dopamine contamination: a paradox resolved. Hypertension 46(2), 355-359 (2005).
123 Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine Oxidase Inhibitors, Tyramine, And Chesse. JAMA 188, 1108-1110 (1964).
124 Asatoor AM, Levi AJ, Milne MD. Tranylcypromine and cheese. Lancet 2(7310), 733-734 (1963).
125 McCabe-Sellers B, Staggs C, Bogle M. Tyramine in foods and monoamine oxidase inhibitor drugs: a crossroad where medicine, nutrition, pharmacy, and food industry converge. J. Food Composit. Anal. 19, S58-S65 (2006).
126 Shulman KI, Tailor SA, Walker SE, Gardner DM. Tap (draft) beer and monoamine oxidase inhibitor dietary restrictions. Can. J. Psychiatry 42(3), 310-312 (1997).
127 Larsen JK. MAO inhibitors: pharmacodynamic aspects and clinical implications. Acta Psychiatr. Scand. Suppl. 345, 74-80 (1988).
128 McDaniel KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin. Neuropharmacol. 9(3), 207-234 (1986).
129 Implementor, package insert. PENTAFARMA, Loures, Portugal.
130 Ivanov SV, Syrkin AL, Drobizhev MIu, Poltavskaia MG, Baturin KA, Burlakov AV. [Pyrazidol in the treatment of depression in patients with ischemic heart disease]. Ter. Arkh. 75(10), 38-42 (2003).
131 Stage KB. Danish University Antidepressant Group. Orthostatic side effects of clomipramine and moclobemide during treatment for depression. Nord. J. Psychiatry 59(4), 298-301 (2005).
132 Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 26(5), 381-394 (2009).
133 Tanghe A, Geerts S, Van Dorpe J, Brichard B, Bruhwyler J, Geczy J. Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psychiatr. Scand. 96(2), 134-141 (1997).
134 Baier D, Philipp M. Modification of sexual functions by antidepressants]. Fortschr. Neurol. Psychiatr. 62(1), 14-21 (1994).
135 deMarcaida JA, Schwid SR, White WB et al.; Parkinson Study Group TEMPO; PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov. Disord. 21(10), 1716-1721 (2006).
136 Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 13(5), 341-355 (1998).
137 Azzaro AJ, Vandenberg CM, Blob LF et al. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J. Clin. Pharmacol. 46(8), 933-944 (2006).
138 Isaacson SH. Selective MAO-B inhibitors have low potential for the tyramine effect. Mov. Disord. 25(1), 123-124 (2010).
139 Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I. Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 66(9), 1427-1429 (2006).
140 Lyons KE, Friedman JH, Hermanowicz N et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin. Neuropharmacol. 33(1), 5-10 (2010).
141 Xiong C, van Belle G, Miller JP, Morris JC. Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease. Clin. Trials 8(1), 15-26 (2011).
201 Selegiline patch for treatment of nicotine dependence. www.clinicaltrials.gov/ct2/show/NCT01330030?term=selegiline&rank=12
202 Rasagiline in the treatment of persistent negative symptoms of schizophrenia. www.clinicaltrials.gov/ct2/show/NCT00492336?term=rasagiline&rank=21
203 A 3 year study to evaluate the safety and efficacy of low dose ladostigil in patients with mild cognitive impairment (MCI). www.clinicaltrials.gov/ct2/show/NCT01429623?term=ladostigil&rank=1
204 Befloxatone Sanofi-Synthelabo discontinued, USA, Europe. IMS R&D Focus Drug News. http://business.highbeam.com/436...- ouverture dans une nouvelle fenêtre
205 Safinamide in levodopa induced dyskinesia in Parkinson's disease subjects (safinamide-LID). www.clinicaltrials.gov/ct2/show/NCT01113320?term=safinamide&rank=1
206 MOTION, safinamide in early idiopathic Parkinson's disease (IPD), as add-on to dopamine agonist (Extension of Trial 27918). www.clinicaltrials.gov/ct2/show/NCT01028586?term=safinamide&rank=8
207 Safety and efficacy study of ladostigil in mild to moderate probable Alzheimer's disease. www.clinicaltrials.gov/ct2/show/NCT01354691?term=ladostigil&rank=2
208 MedTrack. www.medtrack.com
|
Language: | English.
|
Document Type: | Review.
|
Journal Subset: | Pharmacology.
|
ISSN: | 1751-2433
|
NLM Journal Code: | 101278296
|
DOI Number: | https://dx.doi.org/10.1586/ecp.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|